Naoki Niikura

机构：Tokai University, Tokai University Hospital · ORCID：0000-0001-6732-8527

发表论文 273 篇 · 总被引 9947 次 · h-index 36

代表论文

• Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer (2025 · New England Journal of Medicine · 被引 61)
• LBA21 First-line (1L) datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (mTNBC) for whom immunotherapy was not an option: Primary results from the randomised, phase III TROPION-Breast02 trial (2025 · Annals of Oncology · 被引 30)
• LBA16 Giredestrant (GIRE), an oral selective oestrogen receptor (ER) antagonist and degrader, + everolimus (E) in patients (pts) with ER-positive, HER2-negative advanced breast cancer (ER+, HER2– aBC) previously treated with a CDK4/6 inhibitor (i): Primary results of the phase III evERA BC trial (2025 · Annals of Oncology · 被引 19)
• Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial (2026 · Annals of Oncology · 被引 16)
• Giredestrant (GIRE) + palbociclib (PALBO) vs letrozole (LET) + PALBO as first-line (1L) therapy in patients (pts) with estrogen receptor–positive, HER2-negative locally advanced or metastatic breast cancer (ER+, HER2– LA/mBC): Primary analysis of the phase III persevERA BC trial. (2026 · Journal of Clinical Oncology · 被引 4)
• First-line datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC) for whom immunotherapy was not an option: Additional efficacy endpoints from the TROPION-Breast02 study. (2026 · Journal of Clinical Oncology · 被引 3)